Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Share Price Matching Investor Opinion
Jan 03
Have your own idea? Try our Stock Screener
Swedish (OMX) Clinical Research and Equipment Industry Analysis
UpdatedFeb 16, 2025
DataAggregated Company Financials
Companies11
- 7D0.7%
- 3M4.3%
- 1Y6.2%
- YTDn/a
In the last week, the Clinical Research and Equipment industry is up 7.7%, with AddLife up 18%. In the last 12 months, the industry was up 14%. Earnings are forecast to grow by 32% annually.
Industry Valuation and Performance
Has the Swedish Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 16 Feb 2025 | SEK 43.7b | SEK 17.0b | -SEK 1,038,511,426.00 | 42.5x | -42.1x | 2.6x |
| Tue, 14 Jan 2025 | SEK 41.1b | SEK 16.7b | -SEK 1,152,911,426.00 | 43.2x | -35.6x | 2.5x |
| Thu, 12 Dec 2024 | SEK 44.5b | SEK 16.7b | -SEK 1,152,911,426.00 | 51.4x | -38.6x | 2.7x |
| Sat, 09 Nov 2024 | SEK 44.3b | SEK 16.8b | -SEK 958,019,827.00 | 50.7x | -46.3x | 2.6x |
| Mon, 07 Oct 2024 | SEK 47.2b | SEK 16.7b | -SEK 988,175,491.00 | 58.9x | -47.7x | 2.8x |
| Wed, 04 Sep 2024 | SEK 48.6b | SEK 16.7b | -SEK 987,374,492.00 | 61.8x | -49.2x | 2.9x |
| Fri, 02 Aug 2024 | SEK 49.2b | SEK 16.7b | -SEK 1,128,120,510.00 | 61.9x | -43.6x | 2.9x |
| Sun, 30 Jun 2024 | SEK 42.0b | SEK 16.3b | -SEK 1,188,686,510.00 | 55.3x | -35.3x | 2.6x |
| Tue, 28 May 2024 | SEK 43.1b | SEK 16.3b | -SEK 1,188,686,510.00 | 61.1x | -36.2x | 2.6x |
| Thu, 25 Apr 2024 | SEK 37.9b | SEK 16.1b | -SEK 1,234,732,213.00 | 36.3x | -30.7x | 2.4x |
| Sat, 23 Mar 2024 | SEK 38.9b | SEK 16.0b | -SEK 1,122,792,210.00 | 36x | -34.6x | 2.4x |
| Mon, 19 Feb 2024 | SEK 41.0b | SEK 16.0b | -SEK 1,409,735,350.00 | 50.7x | -29.1x | 2.6x |
| Wed, 17 Jan 2024 | SEK 36.9b | SEK 15.5b | -SEK 1,393,723,683.00 | 45.2x | -26.5x | 2.4x |
| Fri, 15 Dec 2023 | SEK 37.4b | SEK 15.5b | -SEK 1,393,723,683.00 | 46.1x | -26.8x | 2.4x |
| Sun, 12 Nov 2023 | SEK 31.2b | SEK 15.4b | -SEK 1,256,647,710.00 | 34x | -24.8x | 2x |
| Tue, 10 Oct 2023 | SEK 25.6b | SEK 15.1b | -SEK 1,134,516,711.00 | 36.6x | -22.6x | 1.7x |
| Thu, 07 Sep 2023 | SEK 29.6b | SEK 15.1b | -SEK 1,133,372,831.00 | 36.6x | -26.1x | 2x |
| Sat, 05 Aug 2023 | SEK 32.1b | SEK 15.1b | -SEK 213,871,038.00 | 46.7x | -150.2x | 2.1x |
| Mon, 03 Jul 2023 | SEK 36.5b | SEK 14.6b | -SEK 172,476,038.00 | 36.1x | -211.7x | 2.5x |
| Wed, 31 May 2023 | SEK 39.0b | SEK 14.6b | -SEK 173,602,038.00 | 39.4x | -224.6x | 2.7x |
| Fri, 28 Apr 2023 | SEK 35.0b | SEK 14.5b | -SEK 110,425,459.00 | 34x | -316.9x | 2.4x |
| Sun, 26 Mar 2023 | SEK 31.9b | SEK 14.6b | -SEK 57,185,459.00 | 31x | -557.6x | 2.2x |
| Tue, 21 Feb 2023 | SEK 41.8b | SEK 14.4b | SEK 826.4m | 36.4x | 50.6x | 2.9x |
| Thu, 19 Jan 2023 | SEK 40.3b | SEK 14.2b | SEK 943.9m | 38.7x | 42.7x | 2.8x |
| Sat, 17 Dec 2022 | SEK 39.4b | SEK 14.1b | SEK 944.3m | 41.5x | 41.7x | 2.8x |
| Mon, 14 Nov 2022 | SEK 40.0b | SEK 14.1b | SEK 936.8m | 42.1x | 42.7x | 2.8x |
| Wed, 12 Oct 2022 | SEK 32.4b | SEK 13.5b | SEK 750.9m | 47.2x | 43.1x | 2.4x |
| Fri, 09 Sep 2022 | SEK 37.5b | SEK 13.5b | SEK 751.3m | 54.5x | 49.9x | 2.8x |
| Sun, 07 Aug 2022 | SEK 43.7b | SEK 13.2b | SEK 667.8m | 44.6x | 65.4x | 3.3x |
| Tue, 05 Jul 2022 | SEK 43.4b | SEK 13.2b | SEK 753.4m | 39x | 57.6x | 3.3x |
| Thu, 02 Jun 2022 | SEK 54.8b | SEK 13.2b | SEK 753.4m | 48.2x | 72.8x | 4.1x |
| Sat, 30 Apr 2022 | SEK 53.3b | SEK 12.7b | SEK 742.5m | 51.9x | 71.8x | 4.2x |
| Mon, 28 Mar 2022 | SEK 60.7b | SEK 11.8b | SEK 746.3m | 53.5x | 81.3x | 5.1x |
| Wed, 23 Feb 2022 | SEK 50.6b | SEK 11.4b | SEK 784.8m | 43x | 64.5x | 4.4x |
Price to Earnings Ratio
64.5x
Current Industry PE
- Investors are relatively neutral on the Swedish Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 2.8x.
Past Earnings Growth
- Total earnings for the Life Sciences Tools and Services industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 14% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Swedish Clinical Research and Equipment compare with similar industries?
| SE Market | 2.63% | |
| Healthcare | -0.20% | |
| Life Sciences | 0.72% | |
| Clinical Research and Equipment | 0.72% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALIF B AddLife | SEK 175.10 | 1.2% +SEK 255.9m | 71.0% | PE84.7x | |
| BICO BICO Group | SEK 34.48 | 7.8% +SEK 175.0m | -27.6% | PS1x | |
| GENO Genovis AB (publ.) | SEK 27.85 | 3.5% +SEK 62.2m | -41.6% | PE65.3x | |
| MAGLE Magle Chemoswed Holding | SEK 34.00 | 3.0% +SEK 20.5m | 21.4% | PE41.7x | |
| AROC AroCell | SEK 0.60 | 9.1% +SEK 11.5m | 48.1% | PS2.7x |